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Retigabine (RTG) is a first-in-class antiepileptic drug that sup-
presses neuronal excitability through the activation of voltage-
gated KCNQ2–5 potassium channels. Retigabine binds to the pore-
forming domain, causing a hyperpolarizing shift in the voltage
dependence of channel activation. To elucidate how the retigabine
binding site is coupled to changes in voltage sensing, we used
voltage-clamp fluorometry to track conformational changes of the
KCNQ3 voltage-sensing domains (VSDs) in response to voltage, reti-
gabine, and PIP2. Steady-state ionic conductance and voltage sensor
fluorescence closely overlap under basal PIP2 conditions. Retigabine
stabilizes the conducting conformation of the pore and the acti-
vated voltage sensor conformation, leading to dramatic decelera-
tion of current and fluorescence deactivation, but these effects are
attenuated upon disruption of channel:PIP2 interactions. These find-
ings reveal an important role for PIP2 in coupling retigabine binding
to altered VSD function. We identify a polybasic motif in the prox-
imal C terminus of retigabine-sensitive KCNQ channels that contrib-
utes to VSD–pore coupling via PIP2, and thereby influences the
unique gating effects of retigabine.
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KCNQ channels are voltage-gated potassium channels thatplay critical roles in regulating the excitability of neuronal,
cardiac, and peripheral smooth muscle tissue. In the nervous
system, KCNQ2 and KCNQ3 subunits are the primary constit-
uents of M channels, which couple various receptor-mediated
signaling pathways to neuronal excitability, usually via altered
levels of membrane PIP2 (1, 2). Mutations in the KCNQ2 and
KCNQ3 genes have been linked to forms of neonatal epilepsy of
varying severity, from benign familial neonatal convulsions
(BFNCs) to epileptic encephalopathy (3, 4). These channels are
located at the axon initial segment and nodes of Ranvier, with
biophysical hallmarks, including activation at subthreshold po-
tentials, lack of inactivation, and relatively slow gating kinetics
(5, 6). Recently, retigabine (RTG) has emerged as a relatively
safe and effective antiepileptic drug, demonstrating the thera-
peutic potential for activating neuronal KCNQ channels to at-
tenuate excitability in disorders such as epilepsy (7–9).
Retigabine and its close structural analog flupirtine are the
first voltage-gated K+ channel openers approved for use in hu-
mans. A detailed understanding of the mechanism of action of
these drugs may guide the development of more effective and
specific channel activators. Previous studies have demonstrated
that retigabine stabilizes the open state of KCNQ2–5 channels,
reflected in a marked shift of the voltage dependence of channel
activation to more negative potentials and in some cases, an
increase of maximal open probability (10–13). The retigabine
binding site has been characterized in several reports, high-
lighting the importance of a binding pocket within the pore
domain anchored by a critical hydrogen bond interaction be-
tween the drug and an S5 tryptophan residue that is conserved in
retigabine-sensitive KCNQ channels (KCNQ2–5) (14–17).
KCNQ channel:PIP2 interactions are essential for channel
activity and have also been highlighted as important modulators
of pharmacological sensitivity to certain KCNQ activators (18).
Retigabine effects on KCNQ channels rely on the presence of
sufficient PIP2, while certain other activators such as Zn-
pyrithione appear to rescue KCNQ currents in the nominal ab-
sence of PIP2 (18). The molecular mechanisms that govern
functional interactions between KCNQ activators, the KCNQ
channel voltage-sensing apparatus, and the essential phospho-
lipid PIP2 have not been investigated.
To investigate the mechanisms underlying the dramatic effects
of retigabine on the voltage sensitivity of KCNQ channels, we
employed voltage-clamp fluorometry (VCF) to directly measure
conformational changes of the voltage-sensing domain (VSD)
and relate these changes to function of the pore in KCNQ3
channels. By assessing the impact of voltage, retigabine, PIP2
levels, and mutation of potential cytosolic residues involved in
VSD–pore coupling, we provide mechanistic insights into the
functional and pharmacological properties of KCNQ channels.
Results
Voltage-Clamp Fluorometry of KCNQ3 Channels. The VCF approach
requires introduction of a fluorophore in a region that is sensitive
to voltage-dependent conformational changes (Fig. 1B, Bottom).
To generate a useful KCNQ3* (refers to KCNQ3[Ala315Thr])
[see Methods (19)] construct for VCF, we tested a series of cys-
teine mutants throughout the extracellular S3–S4 linker (Fig. 1A).
This region was highly sensitive to mutation, with several mutants
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generating ∼100-mV hyperpolarizing gating shifts (Fig. 1A), al-
though we have not explored these large effects any further. The
KCNQ3*[G219C] and [Q218C] mutations were nearly in-
distinguishable from KCNQ3* channels in terms of their voltage
dependence (Fig. 1A) and retigabine response. G219C is ho-
mologous to the mutation successfully used in several VCF
studies of KCNQ1 (20–22). Both the Q218C and G219C sites
reported fluorescence changes, but the most robust signals were
obtained from channels with Q218C (labeled with Alexa Fluor-
488 maleimide, Fig. 1B). This construct was used throughout the
study and is abbreviated as Q3*VCF. We have also tested anal-
ogous mutations in KCNQ2 and KCNQ2/KCNQ3 heteromeric
channels, but the expression of these channels is significantly
lower than KCNQ3* and we have not successfully generated VCF
recordings from these other KCNQ subtypes.
Overlapping Voltage Dependence of the KCNQ3 Voltage Sensor and
Pore. Fluorescence-voltage relationships of Q3*VCF were gen-
erated by holding oocytes at a depolarized potential (+20 mV)
and stepping to a range of hyperpolarizing potentials. This was
required because the strongly shifted voltage dependence of
activation of KCNQ3* in retigabine required long interpulse
intervals at very negative voltages to achieve a stable fluores-
cence baseline, leading to technical difficulties with recording.
We observed a direct overlap in the voltage dependence of the
fluorescence change and conductance (Fig. 2A). This close
overlap of conductance and fluorescence persists in saturating
retigabine concentrations, as both are shifted equally by ap-
proximately −60 mV (Fig. 2 A and E, note that the absolute V1/2
reported here differs somewhat from typical experiments be-
cause of the altered voltage step protocol that was needed). To
highlight this gating shift, sweeps to −60 mV are depicted in red
(Fig. 2A), where retigabine immobilization of VSD movement is
evident. Retigabine decelerates channel closure and voltage
sensor deactivation (Fig. 2B) and modestly accelerates activation
of current and voltage sensor fluorescence (Fig. 2C). Similar to
KCNQ1 (without KCNE1), but unlike the canonical model Kv
channel Shaker, there is a fairly close correlation of voltage
sensor and current signals (ionic currents are overlaid as dashed
lines), although the voltage sensor fluorescence typically exhibits
a minor slow kinetic component (Fig. 2 B and C) and mild sig-
moidal VSD deactivation kinetics in retigabine that are not ap-
parent in ionic currents (Fig. 2B). Unexpectedly, we also
observed that retigabine increases the magnitude of the fluo-
rescence signal (ΔF) in response to a given depolarization (Fig.
2F). As an important control, all effects of retigabine on fluo-
rescence and currents are abolished when retigabine binding is
disrupted by the W265F mutation (Fig. 2 D–F), demonstrating
the requirement for retigabine binding to the pore.
PIP2 Influences Pore Coupling and VSD Movement. The membrane
phospholipid PIP2 is an essential cofactor and regulator of
KCNQ channels. PIP2 is required for pore opening, and its hy-
drolysis underlies Gq-coupled receptor-mediated channel in-
hibition (23, 24). Recent investigations of KCNQ1 suggest this
requirement reflects PIP2-dependent conformational coupling of
the VSD and pore (22, 25). Therefore, we reasoned that PIP2-
dependent coupling might influence transduction of retigabine
binding from the pore to the voltage sensor. To test the influence of
PIP2, we coexpressed Q3*VCF with the Ciona intestinalis voltage-
sensitive phosphatase CiVSP, allowing time-resolved control of
PIP2 levels using depolarization to activate the phosphatase (26). At
depolarized potentials that activate CiVSP, we observed a fluores-
cence deflection that persists even after pore closure is induced by
PIP2 depletion (Fig. 3A). A subsequent identical depolarization
produces a similar fluorescence change but little current, illustrating
that PIP2 is not required for voltage sensor movement (Fig. 3A).
There are important quantitative differences in voltage sensor
fluorescence signals after PIP2 reduction. There is a pronounced
increase in the magnitude of the fluorescence signal that occurs
simultaneously with PIP2 reduction (Fig. 3B). This is not im-
mediately obvious in Fig. 3A because the CiVSP-mediated
Fig. 1. Cysteine scan mutagenesis of KCNQ3* S3–S4 linker residues and identification of Q218C as the ideal position for fluorophore labeling. (A) Con-
ductance–voltage relationships were determined for a series of cysteine mutants in the S3–S4 linker of KCNQ3* (n = 3–4 for each mutant, error bars represent
SEM). (B, Top) Exemplar traces of ionic current (black) and fluorescence (green) from a X. laevis oocyte expressing KCNQ3*[218C] (abbreviated as Q3*VCF in
text and all figures), labeled with Alexa-488 maleimide and depolarized to +40 mV. (Bottom) Cartoon illustration of the VCF technique.















PIP2 depletion is occurring on approximately the same time
scale as activation of current and fluorescence. However, in
oocytes with slower current rundown kinetics, there is a clear
correlation between the time course of current decay and a
second phase of fluorescence unquenching at +100 mV, where
CiVSP becomes activated (Fig. 3B and Fig. S1). This effect is
also apparent in nonuniformly voltage-clamped oocytes, where
artifactual irregular kinetics of CiVSP-mediated current decay
closely mirror kinetics of fluorescence unquenching (Fig. S1). To
confirm that this unexpected behavior was due to PIP2 re-
duction, we performed the same protocol in the absence of
CiVSP (Fig. 3C), and observed that depolarizations to +100 mV
(compared with +20 mV) elicited fluorescence signals with a
much smaller increase in magnitude and lacking the unquench-
ing phase (Fig. 3 B–D). Lastly, we performed a triple pulse
protocol of two depolarizations to +20 mV, separated by a de-
polarization to +100 mV (to reduce PIP2). In this experiment,
PIP2 reduction consistently facilitates the fluorescence signal in
the second +20-mV depolarization (Fig. 3F). A final important
observation, revisited later, is that PIP2 depletion causes accel-
eration of voltage sensor deactivation at −100 mV (Fig. 3G),
while activation kinetics are unaffected. Taken together, these
results highlight that PIP2 influences the dynamics and confor-
mations sampled by the VSD and is required for voltage-
dependent opening.
Retigabine Protects Channels from CiVSP-Mediated Rundown. We
next examined how PIP2 influences transduction of retigabine
binding to changes in voltage sensing. We began by using CiVSP
coexpression to reduce PIP2 and observed that CiVSP effects are
significantly weakened in the presence of retigabine (Fig. 4A). In
this experiment, voltage steps between −140 mV and +100 mV
were delivered, followed by a test pulse to −20 mV to observe
the extent of PIP2 reduction after different prepulses. In control
conditions, this yields a characteristic bell-shaped relationship
(27), reflecting channel activation at modest depolarizations
(insufficient to activate CiVSP), and strong current inhibition at
Fig. 2. Characterization of retigabine (RTG) effects on Q3*VCF fluorescence. (A) Oocytes were clamped at a holding potential of +20 mV [control (ctrl)
condition] or −20 mV (100 μM RTG) and hyperpolarized in −10 mV steps to for 3 s. Exemplar current (black) and fluorescence (green) traces (Top) and
normalized ΔF or G (tail currents) are displayed (Bottom) (n = 6 or 5, ctrl/RTG). (B and C) Sample fluorescence sweeps (solid lines) and currents (dashed lines)
and summary of deactivation kinetics at −140 mV (τ: −254 ± 24 ms in control and 1,440 ± 180 ms in RTG, n = 9 each) and activation kinetics at +40 mV (τ: 178 ±
4 ms in control and 130 ± 5 ms in RTG, n = 5 each) in control (gray) or 100 μM RTG (green). (D) RTG effects on Q3*VCF [W265F] (n = 7 or 8, ctrl/RTG) using the
same protocols as in A. (E) Summary of V1/2 values (ΔF and G) for Q3*VCF and Q3*VCF[W265F] ± 100 μM RTG (Q3*VCF: −62.0 ± 3 mV and −63 ± 3 mV for ΔF
and G in control, respectively, −122 ± 3 mV and −119 ± 2 mV for ΔF and G in 100 μM RTG; Q3*VCF[W265F]: −65 ± 2 mV and −68 ± 2 mV for ΔF and G in
control, −64 ± 2.1 mV and −67 ± 2 mV for ΔF and G in 100 μM RTG). (F) Fluorescence sweeps and ΔF(RTG)/ΔF(control) summary data from depolarizations to
+40 mV from −140 mV in control (gray) or 100 μM RTG (green) for Q3*VCF (1.28 ± 0.06, n = 12) and Q3*VCF[W265F] (1.00 ± 0.02, n = 11).
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positive voltages where CiVSP activity is higher. In the presence
of retigabine, channel activation is observed at more negative
voltages, as expected (due to the retigabine-mediated shift in
channel activation). More importantly, there is prominent
“protection” against current rundown at positive voltages (Fig.
4A), reminiscent of previously reported protective effects of
retigabine against M1 receptor-mediated current rundown (28).
This effect is absent in the W265F mutant (Fig. 4B), demon-
strating that retigabine does not directly inhibit CiVSP, but in-
stead appears to protect channel-associated PIP2.
We exploited the retigabine protection effect to investigate
reciprocal influences of PIP2, retigabine, and potential PIP2-
interacting residues. The cytoplasmic side of KCNQ channels
has a high density of basic residues potentially involved in
PIP2 interaction, and we have focused on the S2–S3 linker and
the proximal C terminus immediately following the S6 helix (Fig.
4 F and G). We performed a charge neutralization scan by
mutating positively charged residues to alanine (Fig. 4 C–E). In
addition, we modified a cluster of basic residues (“KRRK mo-
tif”) in the proximal KCNQ3 C terminus, with sequential double
alanine substitutions, along with a neutralization of all four
residues (termed S6-AARK, S6-KRAA, S6-AAAA). Relative to
KCNQ1, there is a slightly different arrangement of positively
charged side chains in the S2–S3 linker sequence of KCNQ2–5,
and more positive charges in the vicinity of the C-terminal
KRRK cluster (Fig. 4 F and G).
We reasoned that mutation of residues important for PIP2-
mediated coupling of the pore and VSD might also alter reti-
gabine protection against CiVSP-mediated rundown. In the ab-
sence of retigabine, most mutants exhibited prominent CiVSP-
mediated rundown (Fig. 4C). However, we observed a range of
retigabine-mediated protection (Fig. 4D). Most significantly,
multiple mutations in the proximal C terminus abolished
retigabine-induced protection from CiVSP (Fig. 4 C–E). CiVSP-
mediated rundown of the R364A, H367A, S6-AARK, and S6-
KRAA mutants was insensitive to retigabine (Fig. 4E). Also, in
control conditions, the onset of CiVSP-mediated rundown of
these mutants (shown in blue in Fig. 4C) occurred at more
negative voltages than retigabine-protected channels. Thus, dis-
ruption of basic C-terminal residues generally led to greater
susceptibility to CiVSP in both control and retigabine conditions.
An interesting exception in this region was the K358A mutant,
which exhibited very little CiVSP-mediated rundown in either
control or retigabine conditions (Fig. 4 C–E). The protection
effect is retained to varying degrees for all S2–S3 mutants, with
R190A exhibiting slightly weaker protection against CiVSP-
mediated rundown (Fig. 4E). We also measured the effects of
retigabine on the kinetics of CiVSP rundown in more detail (Fig.
S3). The kinetics of the protection effect were noteworthy, as
retigabine did not notably affect the rate of CiVSP-mediated
rundown in any of the mutants. Rather, retigabine application
led to a sustained plateau current in retigabine-protected chan-
nels (such as the S2–S3 linker mutants), in contrast to the
complete current rundown observed in many C-terminal mutants
(Fig. S3).
Basic characterization of the charge neutralization mutants was
consistent with the retigabine protection assay. Neutralization of
S2–S3 linker charges had modest effects on current expression,
Fig. 3. PIP2 depletion alters Q3*VCF fluorescence. (A) Exemplar traces from an oocyte expressing Q3*VCF + CiVSP, subjected to consecutive depolarizations
to +80 mV, highlighting the effects of PIP2 depletion on current (black) and fluorescence (green). (B and C) Exemplar current and fluorescence traces of
Q3*VCF expressed alone (C) or with CiVSP (B), subjected to depolarizations causing weak (+20 mV) or strong (+100 mV) activation of CiVSP. PIP2 depletion at
highly depolarized potentials produces a significant increase in ΔF. (D) Summary of ΔF (+100 mV)/ΔF (+20 mV) for Q3*VCF and Q3*VCF + CiVSP (1.35 ±
0.05 and 1.99 ± 0.02, respectively, n = 4 and 5). (E) A triple-pulse protocol was applied to assess the impact of PIP2 depletion on ΔF magnitude and kinetics, by
comparing the fluorescence signal elicited by a +20 mV depolarization, before and after PIP2 depletion by a pulse to +100 mV. (F) Summary graph displaying
the increase in ΔF magnitude at +20 mV after a PIP2 depleting +100 mV pulse, including paired data points from individual oocytes (0.48 ± 0.06% ΔF
prerundown, 0.66 ± 0.05% ΔF postrundown). (G) Kinetics of activation (+20 mV) and deactivation (−100 mV) before and after a PIP2-depleting pulse (τact:
138 ± 12 ms in control, 153 ± 12 ms in reduced PIP2; τdeact: 311 ± 21 ms in control, 212 ± 12 ms in reduced PIP2).















V1/2 of activation, or response to 100 μM retigabine (Fig. S2). In
contrast, mutation of K248 (S4–S5 linker) and the majority of
basic residues in the proximal C terminus had profound effects: all
except K358A led to >50% reduction in currents, with K248A,
R364A, S6-AARK, and S6-AAAA causing >85% reduction in
currents (Fig. S2A). The S6-AAAA mutation was the most dis-
ruptive, as currents were undetectable in the absence of retiga-
bine, although 100 μM retigabine rescued a small amount of ionic
current and enabled the collection of conductance–voltage rela-
tionships (Fig. S2B). With the exception of K358A, proximal C
terminus mutants attenuated (but did not abolish) the retigabine-
induced shift in V1/2 of activation. We highlight that the C-terminal
mutants that were disruptive to current are the same mutants that
abolished retigabine-mediated protection against CiVSP (Fig. 4 C–
E) and also exhibit CiVSP-mediated rundown at less depolarized
voltages (Fig. 4 C and D). Taken together, these findings suggest an
important relationship between PIP2 and transduction of retigabine
effects to the voltage sensor.
The C Terminus Is Essential for Normal Pore–VSD Coupling. We in-
vestigated the role of the C terminus in the transduction of
retigabine effects in more detail using VCF. Despite extremely
small currents from KRRK cluster mutants, these channels
generated robust voltage-dependent fluorescence signals that
were consistently much larger than signals from Q3*VCF (Fig.
5A). These observations suggest that the mutants express very
well at the cell surface but are likely hampered by weak VSD–
pore coupling. We also observed marked retigabine enhance-
ment of currents in these mutants (Fig. 5C), suggesting a large
proportion of channels fail to open in control conditions, but can
be partially rescued by retigabine.
There were several pronounced differences in the effects of
retigabine on the C-terminal mutant channels. Firstly, the
retigabine-mediated shift of the conductance–voltage relation-
ship was weakened relative to Q3*VCF (Fig. 5 B and D), and this
effect correlated with the impact of mutations on overall channel
function (KRAA channels were more strongly shifted by reti-
gabine than AARK or AAAA channels). The shift of the fluo-
rescence–voltage relationship was also significantly disrupted in
these mutants (e.g., ΔV1/2 = −57 ± 3 mV for Q3*VCF; −30 ±
4 mV for S6-AARK). Particularly in S6-AARK and S6-AAAA
mutants, fluorescence was less disrupted than conductance,
resulting in a ∼10-mV dissociation of FV and GV that became
apparent in the presence of retigabine (Fig. 5 B and D). The FV
Fig. 4. RTG-induced strengthening of channel:PIP2 interactions relies on C-terminal basic residues. (A and B) Oocytes coexpressing CiVSP with Q3*VCF (A) or
Q3*VCF[W265F] (B), were pulsed between −140 and +100 mV for 2 s, followed by a test pulse to −20 mV, in control or 100 μM RTG (n = 5 and n = 6, re-
spectively). Test pulse currents were normalized to the voltage where maximal channel activity was observed. (C and D) Identical protocols as described in A
and B were delivered to oocytes expressing CiVSP together with Q3*VCF mutants in the S2–S3 linker, S4–S5 linker, or C terminus as indicated (shown in E and
color coded by region), in control (C) or 100 μM RTG (D, n = 4–6 for all constructs). (E) Summary of CiVSP induced current rundown at +50 mV, using a protocol
described in Fig. S3. These findings highlight the necessity of C-terminal residues in enabling RTG-mediated PIP2 rundown protection. (F and G) Sequence
alignments highlighting the high density of basic residues in the S2–S3 linker (F, the gating charge transfer center phenylalanine residue is highlighted in gray
for orientation) and C termini (G, a conserved kinking proline is highlighted in gray for orientation) of Kv1.2 and KCNQ1–5 channels.
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and GV relationships were also significantly steeper in the
C-terminal mutants (in control conditions, Q3*VCF fluorescence–
voltage relationship was fit with an effective valence of 1.95 ±
0.08 elementary charges vs. the S6-AARK valence of 3.8 ± 0.1).
Using the effective valence and V1/2 of Boltzmann fits to the fluo-
rescence–voltage relationships, we estimated the energetic effects of
retigabine on the VSD equilibrium for Q3*VCF (ΔΔG = −5.2 ±
0.3 kcal/mol), S6-AARK (ΔΔG = 0.2 ± 0.3 kcal/mol), and S6-
AAAA (ΔΔG = 0.08 ± 0.17 kcal/mol), indicating a strongly at-
tenuated voltage sensor effect of retigabine in these mutants.
KRRK cluster mutants markedly altered the effects of reti-
gabine on VSD kinetics, shown by a detailed comparison of
Q3*VCF and S6-AARK fluorescence (Fig. 6). In Q3*VCF
channels, retigabine causes dramatic deceleration of fluores-
cence deactivation (Figs. 2B and 6 A and B), and leads to the
appearance of mild sigmoidal deactivation kinetics (loss of expo-
nential decay kinetics). In S6-AARK channels, retigabine-mediated
effects on VSD deactivation are strongly attenuated (Fig. 6 A and
B), as no pronounced deceleration or sigmoidal kinetics are ob-
served in the fluorescence signal. In contrast, retigabine effects on
voltage sensor activation kinetics are preserved (even somewhat
accentuated) in S6-AARK mutants, relative to Q3*VCF (Fig. 6 C
and D). Taken together these data suggest that retigabine has di-
chotomous effects on voltage sensor deactivation (possibly medi-
ated by a C-terminal interaction with PIP2) and activation (likely
mediated by a PIP2-independent mechanism).
Residual PIP2-Independent Coupling of Retigabine.Mutations in the
KRRK cluster attenuate but do not completely uncouple effects
of retigabine on the voltage sensor (Fig. 5 B and D). To rule out
the possibility of a persistent PIP2-mediated coupling of retiga-
bine effects (due to incomplete effects of the C-terminal muta-
tions), we exploited the increased susceptibility of S6-AARK
channels to CiVSP-mediated PIP2 rundown (Fig. 4). With CiVSP
coexpression, we recorded Q3*VCF[S6-AARK] fluorescence us-
ing a holding potential of +80 mV (for sustained CiVSP activa-
tion), to test the voltage sensor effects of retigabine with maximal
PIP2 reduction (Fig. 7). There were no detectable KCNQ3
currents, despite very pronounced fluorescence signals (Fig. 7A),
indicating that CiVSP was functioning properly. These data
demonstrate that even in the absence of PIP2, retigabine stabilizes
VSD activation leading to a −31.1 ± 1.9 mV ΔV1/2 of the fluo-
rescence–voltage relationship (Fig. 7B). This was similar to the
shift observed in S6-AARK channels without CiVSP (Fig. 5D,
ΔV1/2 = −30.4 ± 3.8 mV), but significantly less than the maximal
shift of −57 ± 3 mV in Q3*VCF.
Structural Basis for PIP2-Mediated VSD–Pore Coupling. Overall, the
charge neutralization scan highlights the importance of charged
residues in the proximal C terminus for channel function and
suggest this region is important for normal transduction of reti-
gabine binding to altered VSD function (Figs. 4–6). The recent
appearance of a cryo-EM structure of the related KCNQ1 channel
Fig. 5. RTG effects on the VSD are partially mediated by C-terminal residues involved in VSD–pore coupling. (A) Exemplar current (black) and fluorescence
(green) recordings obtained from Q3*VCF with charge neutralizations in their S6-KRRK motifs. Voltage steps to −60 mV are highlighted red in all conditions
to illustrate the RTG-induced shifts in the voltage dependence of ΔF, which persist even as pore function is progressively lost. (B) Summary graphs of the
voltage and RTG dependence of ΔF and G for mutants shown in A (n = 4–10 per mutant). (C) Summary of 100 μM RTG-induced enhancement of current at
+20 mV for S6-WT (1.4 ± 0.3), S6-KRAA (2.3 ± 0.6), S6-AARK (8.4 ± 0.9), and S6-AAAA (immeasurable due to absence of currents in 0 RTG) (n = 4–10). (D) V1/2
values for ΔF and G, highlighting the RTG-mediated shift in fluorescence (green lines). ΔV1/2 for FV relationships were −57 ± 3 mV (Q3*VCF), −41 ± 7 mV (S6-
KRAA), −30 ± 4 mV (S6-AARK), and −34 ± 2 mV (S6-AAAA). ΔV1/2 for GV relationships were −60 ± 4 mV (Q3*VCF), −47 ± 5 mV (S6-KRAA), and −20 ± 3 mV (S6-
AARK) (*P < 0.05 for ΔV1/2 compared with Q3*VCF FV or GV as indicated, using ANOVA and Dunnett’s post hoc test).















in complex with calmodulin provides a very useful template for
understanding the orientation of the KCNQ channel C terminus
relative to the pore and VSD (29) (Fig. 8). We originally suspected
that the rich density of positively charged side chains in the S2–
S3 linker might influence channel function and retigabine sensi-
tivity via PIP2 interactions. However, our experimental findings
suggest this is not a prominent effect (Fig. 4 and Fig. S2), and in
the cryo-EM structure this motif appears to be primarily involved
in forming an interface with calmodulin rather than interacting
with the C terminus. The KRRK cluster is located just before an
IQ-like motif previously suggested to mediate calmodulin inter-
actions with KCNQ channels (30–32). Although the cryo-EM
structure is not in complex with PIP2, multiple basic residues,
including the KRRK cluster, K248 (S4–S5 linker), and R243 (the
second arginine in a RR motif conserved in retigabine-sensitive
KCNQ channels, at the intracellular end of S4), orient toward a
pocket that is a good candidate for a PIP2 binding site that could
couple the C-terminal KRRK motif with elements of the voltage
sensor and S4–S5 linker (Fig. 8). A PIP2-dependent mechanism of
coupling between the C terminus and voltage-sensing apparatus
provides a rationale for both poor efficiency of channel opening
in KRRK cluster mutants (Fig. S2) or PIP2 reduction (Fig. 3).
Moreover, stabilization of this configuration by retigabine would
account for the protection of PIP2 against CiVSP-mediated run-
down and the loss of protection after neutralization of critical
C-terminal or S4–S5 linker residues (Fig. 4). The model highlights
our suggestion of PIP2-dependent “bridging” of the C terminus
and voltage sensor, which may constrain the voltage sensor, and
Fig. 6. Kinetic effects of retigabine in Q3*VCF and S6-AARK mutant channels. (A) Exemplar sweeps depicting VSD fluorescence deactivation kinetics at
indicated voltages in Q3*VCF and S6-AARK channels, and the influence of retigabine. (C) Exemplar sweeps depicting VSD fluorescence activation kinetics at
indicated voltages in Q3*VCF and S6-AARK channels. Summary data (mean + SEM) is presented in B and D (n = 5 per condition).
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also allow pore binding of retigabine to exert its dramatic effect on
voltage sensor deactivation kinetics.
Discussion
Retigabine is a powerful opener of neuronal KCNQ channels,
with a well-defined binding site in the channel pore (14, 15, 33).
However, mechanisms that couple the pore to the voltage
sensing domain, and link retigabine binding to altered voltage
sensitivity, are poorly understood. Previous investigations of
voltage sensing in KCNQ channels have focused primarily on
KCNQ1, demonstrating that VSD movements in KCNQ1 are
dynamically regulated by association with auxiliary subunits such
as KCNE1/3 and by PIP2, which affect not only the VSD re-
sponse to voltage, but also coupling of VSD movements to
opening of the pore gate (20–22, 34, 35). Although neuronal
KCNQ channels like KCNQ3 share this requirement for PIP2,
their unique sensitivity to retigabine provides a tool to identify
structural motifs that govern the interplay between voltage
sensing, pharmacology, and regulation by PIP2.
We found that retigabine shifts the voltage dependence of
Q3*VCF fluorescence in parallel with channel conductance,
demonstrating drug-mediated stabilization of the activated voltage
sensor. At ambient PIP2 levels, KCNQ3 activation was modulated
over a wide voltage range with retigabine, and close overlap of
the voltage dependence of pore opening and voltage sensor
fluorescence was retained (Fig. 2A). This close overlap resembles
observations made in KCNQ1 in the absence of KCNE1 (21).
Disruption of channel:PIP2 interactions caused significant
changes of voltage sensor dynamics and pore gating that we
describe colloquially as “unhinging” of the voltage sensor from
the pore.
An obvious feature of the unhinged voltage sensor was a sig-
nificantly increased magnitude of the fluorescence signal (Fig. 3
B–E). We suggest that this effect reflects the adoption of novel
VSD conformations when constraints imposed by PIP2-dependent
pore:VSD coupling are removed. The extracellular environment
around the fluorescent tag was not manipulated in these experi-
ments, so it seems reasonable to infer that the much larger fluo-
rescence signals after PIP2 reduction (Fig. 3, or disruptive
C-terminal mutations such as S6-AARK, Figs. 5–7) indicate a
significant change in VSD conformation when uncoupled from the
pore. It is noteworthy that KCNQ1 channels (tagged at the
Fig. 7. RTG activates the VSD in “PIP2-less” Q3*VCF [S6-AARK] channels.
(A) Effects of RTG on the voltage dependence of ΔF from Q3*VCF [S6-AARK]
was assessed under PIP2-depleted conditions (by coexpression with CiVSP,
using a holding potential of +80 mV for sustained CiVSP activation). Exem-
plar currents (black) and fluorescence (green) recordings are shown, but no
KCNQ currents were detectable. (B) Summary of FV relationships in control
and 100 μM RTG, highlighting the RTG-induced shift in the absence of PIP2
(ΔV1/2 = −31 ± 2 mV, n = 4).
Fig. 8. Proposed PIP2 binding region in a model of KCNQ3. A homology
model of KCNQ3 was generated based on a cryo-EM structure of KCNQ1
(PDB 5VMS). Highlighted residues in the proximal C terminus (R371) and S4–
S5 linker (K248) were found to have a perturbative effect on current
magnitude and retigabine protection against CiVSP-mediated rundown.
Other basic amino acid residues delineating a pocket that may accom-
modate a PIP2 headgroup are highlighted (S4 residue R243). R183 is
predicted to be the closest S2–S3 linker residue to this pocket but would
be largely occluded by the associated calmodulin subunit (depicted in
blue). A hypothesized PIP2 headgroup has been positioned manually in
this potential binding pocket to illustrate the approximate dimensions
and to highlight our hypothesis.















equivalent position) also exhibit much larger fluorescence changes
than we observe in Q3*VCF (20). Although not yet tested directly,
one interesting explanation could be the critical KRRX sequence
that is present in KCNQ2–5, but not KCNQ1, that may constrain
voltage sensor movement relative to KCNQ1 (Figs. 3 and 4).
Further evidence for significant impact on voltage sensor function
is that the KRRK cluster mutants exhibit steeper fluorescence–
voltage relationships compared with Q3*VCF (Fig. 5).
A second feature of the unhinged voltage sensor is altered
deactivation kinetics of voltage sensor fluorescence after PIP2
breakdown (Fig. 3G) or in KRRK neutralizations such as S6-
AARK (Fig. 6). Moreover, deactivation of the unhinged voltage
sensor is not strongly decelerated by retigabine, unlike the
dramatic effects on Q3*VCF deactivation (Fig. 6). A previous
study reported that PIP2 rundown prevents retigabine activation
of KCNQ2 channels (36). We were thus surprised to find that
despite our best efforts to reduce PIP2 and unhinge the voltage
sensor, there was a persistent (although weakened) retigabine-
mediated hyperpolarizing shift of the VSD, even in the absence
of ionic current (Fig. 7). The shift appears to be due primarily
to acceleration of VSD activation kinetics, rather than de-
celeration of deactivation (Fig. 6), implying that retigabine
binding to the pore is communicated in multiple ways to the
VSD. Our findings suggest separable PIP2-dependent and PIP2-
independent modes of coupling between the KCNQ pore and
voltage sensors, which predominantly affect deactivation or ac-
tivation, respectively (Figs. 6 and 7).
The convergent effects of KRRK mutations and PIP2 de-
pletion in terms of channel function, voltage sensor deactivation,
and weakened PIP2 protection, might be rationalized with a
structural model as shown (Fig. 8). We suggest that a PIP2-
mediated association between the C terminus (adjacent to the
S6 gate) and the VSD is essential for normal channel function
and sensitivity to retigabine. When PIP2 is abundant, reciprocal
interactions between the VSD, PIP2, and pore, may be reflected
in closely overlapping fluorescence– and conductance–voltage
relationships (Fig. 2). An intuitive explanation is that when the C
terminus can closely engage with the voltage sensor (via PIP2),
mutual constraints on their motions cause them to operate with
similar voltage dependence. However, when PIP2 interactions
are disrupted, we suggest that these constraints are weakened or
lost, leading to dissociation of FV and GV relationships in cer-
tain conditions (Fig. 5 A and B, notably S6-AARK or S6-AAAA
in retigabine). PIP2-independent effects of retigabine on VSD
activation (Fig. 6) persist in these mutants, but do not efficiently
open channels due to the lack of PIP2 (Fig. 5). Thus, there is
likely a large fraction of voltage sensors that generate a fluo-
rescence signal, but do not influence a PIP2-coupled gate.
Moreover, the large increase in fluorescence in PIP2-reduced
conditions (Fig. 3B) suggests that the fluorescence signal from
unhinged voltage sensors is larger and this effect may accentuate
differences of the FV relative to the GV. Most importantly, even
after fairly significant rescue of current by retigabine (see S6-
KRAA or S6-AARK in Fig. 5A) the open pore and active
voltage sensor are not well stabilized by the drug. This is sup-
ported by the deactivation of ionic tail currents (Fig. 5A) and
VSD fluorescence (Fig. 6 A and B), as both are much faster than
Q3*VCF (Fig. 2 A and B). The influence of retigabine toward
stabilizing the engaged C terminus:PIP2:VSD arrangement also
emerges in the protection of PIP2 against CiVSP-mediated
breakdown (Fig. 4). As mentioned, this mirrors earlier charac-
terizations of retigabine demonstrating protection against M1
receptor-mediated rundown (28). This observation may have
important implications related to the therapeutic drug
mechanism, suggesting that in addition to silencing neurons
through KCNQ channel activation, retigabine may blunt
sensitivity to signaling cascades that operate through PLC-
mediated PIP2 breakdown.
We did not observe dramatic effects of S2–S3 linker mutations,
although certain mutants, such as R190A, exhibited both weaker
PIP2 protection and less overall current (Fig. 4 and Fig. S2). These
residues may be candidates for future investigation, although the
cryo-EM structure suggests that the S2–S3 linker does not directly
interact with the KRRKmotif or other elements of the C terminus
(Fig. 8). In the context of the recent structure, an important issue
to unravel will be whether calmodulin plays a role in mediating
interactions between the C terminus and VSD. PIP2 and cal-
modulin may compete in this region, as reported recently for
KCNQ1 (37), or interact in some other cooperative manner, with
calmodulin contributing to the functional interaction between the
C terminus and voltage sensor that we have observed here. Pre-
vious work has proposed that the S4–S5 linker also contributes to
channel–PIP2 interactions in KCNQ2 and KCNQ3 (18, 36). This
is supported by our observation that the S4–S5 linker K248A
mutation weakened channel function and retigabine action (Fig.
4E and Fig. S2).
Collectively, our findings demonstrate that retigabine actions
are strongly influenced by a PIP2-mediated interaction between
the pore and VSD, specifically involving a cluster of basic resi-
dues in the C terminus of retigabine-sensitive KCNQ channels.
The presence of PIP2 is essential for channel opening and affects
transduction of retigabine binding to stabilization of the activated
conformation of the VSD. Perturbation of this lipid-mediated
coupling mechanism causes uncoupling of the pore and VSD in
certain conditions and a significant attenuation of retigabine ef-
fects. These findings reveal fundamental details of voltage- and
lipid-dependent gating in KCNQ channels, together with essential
structural determinants underlying retigabine action.
Methods
Molecular Biology. KCNQ3 channel cDNA constructs were expressed using the
pSRC5 vector (gifts from M. Taglialatela, University of Molise, Campobasso,
Italy, and T. Jentsch, Leibniz-Institut für Molekulare Pharmakologie, Berlin).
In all experiments, the Ala315Thr mutation was introduced to enable effi-
cient KCNQ3 functional expression without coinjection of KCNQ2 mRNA
{throughout the text we refer to KCNQ3[Ala315Thr] as KCNQ3*}. For VCF
recordings, the KCNQ3[A315T][Q218C] mutation was used, and is referred to
as Q3*VCF throughout the text. The plasmid encoding CiVSP was kindly
provided by Y. Okamura, Osaka University, Osaka. cRNA was transcribed
from the cDNA using the mMessage mMachine kit (Ambion). Stage V–VI
Xenopus laevis oocytes were prepared as previously described and injected
with 50 ng of channel cRNA with or without 15 ng CiVSP cRNA. After injection,
oocytes were incubated for 24–72 h at 17 °C before recording.
Two-Electrode Voltage Clamp and VCF. Voltage-clamped potassium currents
were recorded in modified Ringer’s solution (in millimoles): 116 NaCl, 2 KCl,
1 MgCl2, 0.5 CaCl2, 5 Hepes (pH 7.4) using an OC-725C voltage clamp
(Warner). Glass microelectrodes were backfilled with 3 M KCl and had re-
sistances of 0.1–1 MΩ. Data were filtered at 5 kHz and digitized at 10 kHz
using a Digidata 1440A (Molecular Devices) controlled by pClamp 10 soft-
ware (Molecular Devices). Retigabine was purchased from Toronto Research
Chemicals and stored as 100-mM stocks in DMSO and diluted to working
concentrations each experimental day. For VCF, X. laevis oocytes expressing
Q3*VCF were incubated in 100 μM Alexa Fluor-488 maleimide (Thermo
Fisher Scientific) for 20 min in a depolarizing high K+ modified Ringer’s
solution (in millimoles): 100 mM KCl, 1 MgCl2, 0.5 CaCl2, 5 Hepes (pH 7.4).
Following labeling, oocytes were thoroughly rinsed in standard Ringer’s
solution and kept on ice for prompt use. Fluorometry was simultaneously
performed with a two-electrode voltage clamp on an Olympus IX51 inverted
microscope. A PhlatLight LED (Luminus Devices) powered by a DC power
supply (F25-12-AG; Bel Power Solutions) served as the light source, and
emitting light from the oocyte animal pole was collected and amplified as an
electric signal using a PIN040-A photodiode (OSI Optoelectronics) connected
to a patch-clamp head unit/amplifier in voltage-clamp mode (Axopatch-1C;
Axon instruments).
Data Analysis. Voltage dependence of channel activation and normalized
fluorescence change was fitted with a standard single component Boltzmann
equation of the form G/Gmax = 1/(1 + e[−(V − V1/2
)/k]), where V1/2 is the voltage
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where channels exhibit half-maximal activation, and k is a slope factor
reflecting the voltage range over which an e-fold change is observed.
Fluorescence data were low-pass filtered at 20 Hz and adjusted for bleaching
by subtracting a linear component fitted to the baseline fluorescence at the
beginning and end of each voltage sweep. To minimize the impact of
bleaching, only data from cells displaying a >0.5%maximal ΔF were used for
analysis. ΔF values were obtained by dividing the maximal fluorescence
change at the end of the test pulse by the baseline fluorescence preceding
the test pulse, from single nonaveraged sweeps. Statistical tests and signif-
icance are described in figure legends throughout the text.
Construction of Molecular Model. The molecular model of KCNQ3 was gen-
erated using a homology model of KCNQ3 based on the recently published
cryo-EM structure of KCNQ1 in complex with calmodulin (Protein Data Bank
5VMS) using the online SWISS-MODEL tool (https://swissmodel.expasy.org)
(38). An energy-minimized conformation of the PIP(4,5)2 headgroup was
manually docked into the KCNQ3 molecular model for illustration of the
dimensions of the pocket and visualization of our hypothesis. We emphasize
that this is a preliminary structural model intended to illustrate our hy-
pothesis, and that much further development and refinement of the model
will be possible as further constraints are collected.
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